Innovex International, Inc. (INVX)
Valuation Overview•Is Innovex International, Inc. Overvalued or Undervalued?
Trading at a discount to intrinsic cash flow value, implying pessimistic long-term market expectations.
Moderate quality score of 66/100, reflecting stable operating margins and manageable leverage.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Solid fundamental quality, though profitability presents a headwind.
Wall Street is highly bullish, projecting significant upside alongside robust expected earnings growth. The company currently dilutes shareholders to fund operations and growth rather than returning capital.
INVX demonstrates adequate business quality with stable profitability. This is backed by a fortress balance sheet, holding significant net cash ($83M) and minimal debt risk.
The company is driving exceptional top-line expansion (27.9% 3Y CAGR) however, earnings have severely contracted over the same period. Operating efficiency remains adequate with margins around 10.8%.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $239.0M | +48.0% | +27.9% | +21.8% | +1.5% | |
| EBITDA | $42.8M | — | +20.1% | — | — | |
| Net Income | -$16.7M | -40.6% | +9.6% | — | -8.0% | |
| EPS (Diluted) | $-0.24 | -56.7% | -33.3% | — | -13.3% | |
| Free Cash Flow | $14.0M | +95.1% | — | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 28.7% | 31.7% | 31.7% | 31.5% |
| Operating Margin | 10.8% | 12.2% | 11.5% | 6.0% |
| Net Margin | 5.3% | 14.4% | 12.0% | 2.2% |
| FCF Margin | 14.9% | 13.0% | 6.5% | 8.7% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $0.23 | $0.34 | +47.8% | ||
| Q1'26 | $0.29 | $0.20 | -31.0% | ||
| Q4'25 | $0.27 | $0.18 | -33.3% | ||
| Q3'25 | $0.27 | $0.28 | +3.7% | ||
| Q2'25 | $0.32 | $0.29 | -9.4% | ||
| Q1'25 | $0.26 | $0.47 | +80.8% | ||
| Q4'24 | $0.26 | $0.25 | -3.8% | ||
| Q3'24 | $0.11 | $0.10 | -7.1% |
Total return is +58.0% (1Y), outperforming the benchmark by +33.0%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +12.2% | +2.9% | — |
| 1Y | +58.0% | +33.0% | — |
| 3YCAGR | +20.0% | +1.3% | — |
| 5YCAGR | +11.5% | -0.4% | — |
| 10YCAGR | +5.6% | -7.8% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Innovex International, Inc. (INVX) valuation, health, and returns.
Innovex International, Inc. is estimated to be undervalued under our discounted cash flow framework. relative multiples indicate the stock is Fair versus peers compared to industry peers. undervalued (implying +39.2% upside to DCF intrinsic value of $35.59)
Innovex International, Inc. has multiple valuation anchors: DCF Intrinsic Value: $35.59 | Peer Relative Fair Value: $25.81 | Wall Street Analyst Target: $31.33 (implying +22.5% upside). A convergence of these signals offers higher conviction.
Innovex International, Inc. displays good financial health with a composite quality score of 66/100, supported by a Altman Z-Score of 6.9 (safe zone), Piotroski F-Score of 5/9, Return on Invested Capital (ROIC) of 8.7%.
Innovex International, Inc. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Innovex International, Inc.'s current growth trajectory is Accelerating. The company achieved +48.0% 1Y revenue growth and -56.7% 1Y EPS growth, compared to its 3Y revenue CAGR of +27.9%.
Wall Street consensus is Buy based on 2 analysts, beating EPS expectations in 25% of recent quarters with a 1-quarter streak. The consensus price target represents a +22.5% change from current levels.
Investment risks for Innovex International, Inc. include: -17.9% 1-year max drawdown. Volatility risk is characterized by a beta of 0.84x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.